All In Biotech

Drug Trial Radar · NCT01964989

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

Last checked: Nov 20, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,644 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,644

Actual

Start

Nov 2013

Primary completion

Oct 2015

Study completion Aug 2016

Sponsor

Lead sponsor
SeqirusIndustry
Sponsor type
Industry
Collaborators
Novartis Vaccines
First posted
Oct 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.

Conditions

  • Influenza Virus

Interventions

  • Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)Biological

    1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

  • Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)Biological

    1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Endpoint: First-Occurrence Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Confirmed Influenza A and/or B of Any Influenza Strain in Subjects ≥6 to <72 Months of AgeTime frame: ≥21 days and ≤180 days after the last vaccination or until the end of the influenza season (Northern Hemisphere: end of June; Southern Hemisphere: end of December; Philippines/Thailand: end of October), whichever was longer

Locations

167 sites in 11 countries. Site status is shown where the registry gives one.

  • 222, Novartis Investigational Site

    Chandler, Arizona

  • 267, Novartis Investigational Site

    Harrisburg, Arkansas

  • 259, Novartis Investigational Site

    Anaheim, California

  • 280, Novartis Investigational Site

    Anaheim, California

  • 213, Novartis Investigational Site

    Baldwin Park, California

  • 407, Novartis Investigational Site

    Downey, California

  • 238, Novartis Investigational Site

    La Puente, California

  • 411, Novartis Investigational Site

    Ontario, California

  • 202, Novartis Investigational Site

    Paramount, California

  • 250, Novartis Investigational Site

    San Diego, California

  • 293, Novartis Investigational Site

    San Francisco, California

  • 243, Novartis Investigational Site

    Colorado Springs, Colorado

  • 249, Novartis Investigational Site

    Denver, Colorado

  • 229, Novartis Investigational Site

    Boca Raton, Florida

  • 416, Novartis Investigational Site

    Hialeah, Florida

  • 287, Novartis Investigational Site

    Hialeah, Florida

  • 412, Novartis Investigational Site

    Homestead, Florida

  • 224, Novartis Investigational Site

    Melbourne, Florida

  • 417, Novartis Investigational Site

    Miami, Florida

  • 404, Novartis Investigational Site

    Miami, Florida

  • 285, Novartis Investigational Site

    Miami, Florida

  • 277,Novartis Investigational Site

    Miami, Florida

  • 234, Novartis Investigational Site

    Opa-locka, Florida

  • 297, Novartis Investigational Site

    Orlando, Florida

  • 297, Novartis Investigational vaccine

    Orlando, Florida

  • 410, Novartis Investigational Site

    Sarasota, Florida

  • 401, Novartis iNvestiagtional Site

    Atlanta, Georgia

  • 299, Novartis Investigational Site

    DeKalb, Illinois

  • 268, Novartis Investigational Site

    Peoria, Illinois

  • 209, Novartis Investigational Site

    Augusta, Kansas

  • 210, Novartis Investigational Site

    Newton, Kansas

  • 274 Novartis Investigational Site

    Park City, Kansas

  • 211, Novartis Investigational Site

    Wichita, Kansas

  • 269, Novartis Investigational Site

    Bardstown, Kentucky

  • 226, Novartis Investigational Site

    Louisville, Kentucky

  • 248, Novartis Investigational Site

    Louisville, Kentucky

  • 207, Novartis Investigational Site

    Louisville, Kentucky

  • 290, Novartis Investigational Site

    Louisville, Kentucky

  • 265, Novartis Investigational Site

    Haughton, Louisiana

  • 408, Novartis Investigational Site

    Mangham, Louisiana

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.